Blueprint Medicines
Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.
Launch date
Employees
Market cap
€4.8b
Enterprise valuation
€4.6b (Public information from Sep 2024)
Share price
$90.94 BPMC
Cambridge Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 794m | 180m | 204m | 249m | 496m | 687m | 936m |
% growth | 1093 % | (77 %) | 13 % | 22 % | 99 % | 39 % | 36 % |
EBITDA | 309m | (634m) | (529m) | (470m) | (227m) | (93.1m) | 98.5m |
% EBITDA margin | 39 % | (352 %) | (259 %) | (189 %) | (46 %) | (14 %) | 11 % |
Profit | 314m | (644m) | (558m) | (507m) | (98.2m) | (117m) | 51.9m |
% profit margin | 40 % | (358 %) | (273 %) | (203 %) | (20 %) | (17 %) | 6 % |
EV / revenue | 6.8x | 32.4x | 8.9x | 20.6x | 10.6x | 7.7x | 5.5x |
EV / EBITDA | 17.4x | -9.2x | -3.4x | -10.9x | -23.3x | -56.7x | 52.0x |
R&D budget | 327m | 601m | 477m | 428m | - | - | - |
R&D % of revenue | 41 % | 334 % | 234 % | 172 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$40.0m | Series A | ||
N/A | Early VC | ||
$25.0m | Series B | ||
$50.0m | Series C | ||
N/A | $147m Valuation: $398m | IPO | |
N/A | $135m | Post IPO Equity | |
N/A | $216m | Post IPO Equity | |
N/A | $326m | Post IPO Equity | |
N/A | $327m | Post IPO Equity | |
$1.3b Valuation: $1.3b 6.9x EV/LTM Revenues -2.0x EV/LTM EBITDA | Post IPO Equity | ||
Total Funding | €105m |
Related Content
Recent News about Blueprint Medicines
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Blueprint Medicines
EditACQUISITION by Blueprint Medicines Nov 2021